Garrett focuses his practice on corporate law, transactional work, including private sales and acquisitions, and general corporate matters including reorganizations, corporate governance issues and commercial contracts. He represents private equity clients as well as clients across the energy and sustainability, life sciences and technology industries.
While attending law school, Garrett served as a legal intern with a biopharmaceutical company focused on developing cancer treatments. In that role, he assisted in the implementation of a globally compliant privacy program and with the assessment and reporting of an international data privacy incident. He was also a legal intern at a pharmaceutical company that is developing medicine to control the expression of genes. In that role, he negotiated and drafted commercial contracts and implemented a contract management system.
Prior to attending law school, Garrett worked as a business analyst in supply chain operations with a California-based global information technology company, a business analyst with a Canadian multinational financial services company, and a document control officer in the corporate financing division of a Canadian multinational bank.
Experience
- Represented Liberty Power, an independent retail electricity supplier, in its negotiation of a multi-year supply agreement with Boston Energy Trading and Marketing LLC, restructuring of its existing capital structure, and entry into new financing arrangements.
- Represented a national distributed solar developer in its acquisitions of solar energy Project Companies in New York, Massachusetts, New Hampshire, Maryland, Pennsylvania and Texas.
- Represented cloud computing company Rocket Innovations, Inc. in the sale of Rocketbook, the leading smart reusable notebook brand in the United States, to BIC, a global manufacturing company of disposable consumer products such as stationery, lighters, and shavers.
- Represented Capstone Partners, an investment banking and advisory firm serving middle market companies, in its sale to Huntington Bancshares Incorporated (Nasdaq: HBAN).
- Represented Albireo Pharma, a biotechnology company focused on developing treatments for rare disease in its sale to French biotechnology firm Ipsen SA.
- Represented Med-Pharmex, a manufacturer of generic veterinary drugs and portfolio company of private equity firm DW Healthcare Partners, in its sale to Dechra Pharmaceuticals, a British-owned developers and manufacturer of veterinary products.
- Represented XL Fleet Corp., a developer and manufacturer of vehicle electrification solutions, in its de-SPAC merger with Pivotal Investment Corporation II, a special purpose acquisition company.
viewpoints
Energy & Sustainability Legal Feature — Recently Announced Clean Hydrogen Hub Program Funding
October 13, 2022 | Article | By Garrett Galvin, Alana D. Agron
Read about the Biden-Harris administration’s announcement of $7 billion in funding to create regional clean hydrogen hubs (“H2Hubs”)
Stock Vesting in Startup Companies
March 15, 2022 | Article | By Alex Civetta, Garrett Galvin
The Beauty and the Terror of Agile Software Development
March 24, 2021 | Advisory | By Alex Civetta, Garrett Galvin
DC Circuit Vacates Trump Administration’s Affordable Clean Energy Rule
February 3, 2021 | Blog | By Garrett Galvin
USCIT Ruling Permits Implementation of Trump Administration’s Bifacial Solar Tariffs
November 30, 2020 | Blog | By Garrett Galvin
FERC Order Removes Barriers for Distributed Energy Resource Aggregations in Wholesale Markets
September 30, 2020 | Blog | By Garrett Galvin
Petition Seeks Federal Overturn of Net Metering, Calls into Question Federal vs. State Authority Over Solar Sales
July 8, 2020 | Blog | By Garrett Galvin
News & Press
Mintz Advises DW Healthcare Partners on Continuation Fund
December 05, 2024
Mintz advised DW Healthcare Partners (DW) on the organization of a continuation vehicle to extend DW’s investment in its portfolio company, Med Learning Group, a continuing medical education company, and to provide additional capital to support the company’s further development and growth.
Mintz advised Artemis Capital Partners, a Boston-based private equity firm focused on partnering with differentiated industrial tech companies, on its acquisition of Diamond Antenna and Microwave Corporation, a developer of advanced radio frequency rotary joints and rotating subsystems serving mission critical ground, shipboard, submarine, aircraft, commercial, and space applications.
Mintz Advises Invited, Inc. in its Sale of Certain Assets Related to its BigShots Golf Business to Topgolf Callaway Brands Corp.
November 03, 2023
WASHINGTON, DC – Mintz served as legal counsel to Invited, Inc. in its sale of certain assets related to its BigShots Golf business to Topgolf Callaway Brands Corp.
BOSTON– Mintz represented Gradiant Corporation, a global end-to-end solutions provider of advanced water and wastewater treatment, in its Series D financing.
Deal Diary: Orrick, Paul Weiss, Mintz On Ipsen Deal For Albireo
January 9, 2023
Mintz's role acting for biotechnology company Albireo Pharma in its sale to Ipsen was covered in The Deal. The article featured Mintz Members Megan Gates, and John Condon and Associate Garrett Galvin, who led for the firm.
Mintz Takes Lead For Med-Pharmex In Its Sale To Britain’s Dechra
August 31, 2022
Mintz completed a deal as counsel to Med-Pharmex in its sale to British-owned veterinary products developer and manufacturer Dechra Pharmaceuticals. Through the sale, Dechra will gain further access and nearly 40 years of experience in the U.S. veterinary health market.
Mintz's interdisciplinary team continues its leadership role in life sciences, serving as legal counsel to ProKidney LP in its $2.6 billion SPAC merger, and its subsequent listing on the Nasdaq under the ticker symbol "PROK". ProKidney is a leading clinical-stage cellular therapeutics company focused on chronic kidney disease. ProKidney's lead product candidate is in Phase 3 clinical development and has the potential to slow, stabilize and reverse decline in kidney function
The deal will take public ProKidney, a leading clinical-stage cellular therapeutics company focused on chronic kidney disease, and is expected to provide up to $825 million in gross cash proceeds.